Total Valuation
Xeris Pharmaceuticals has a market cap or net worth of $1.39B. The enterprise value is $1.54K.
Market Cap$1.39B
Enterprise Value$1.54K
Share Statistics
Xeris Pharmaceuticals has 172,642,060 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding172,642,060
Owned by Insiders5.39%
Owned by Institutions0.98%
Financial Efficiency
Xeris Pharmaceuticals’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is 8.89%.
Return on Equity (ROE)0.04
Return on Assets (ROA)<0.01
Return on Invested Capital (ROIC)8.89%
Return on Capital Employed (ROCE)0.09
Revenue Per Employee670.91K
Profits Per Employee1.27K
Employee Count435
Asset Turnover0.76
Inventory Turnover0.78
Valuation Ratios
The current PE Ratio of Xeris Pharmaceuticals is 114.1. Xeris Pharmaceuticals’s PEG ratio is -22.22.
PE Ratio114.1
PS Ratio4.32
PB Ratio92.00
Price to Fair Value92.00
Price to FCF45.09
Price to Operating Cash Flow20.62
PEG Ratio-22.22
Income Statement
In the last 12 months, Xeris Pharmaceuticals had revenue of 291.85M and earned 554.00K in profits. Earnings per share was <0.01.
Revenue291.85M
Gross Profit238.43M
Operating Income24.90M
Pretax Income554.00K
Net Income554.00K
EBITDA12.71M
Earnings Per Share (EPS)<0.01
Cash Flow
In the last 12 months, operating cash flow was 66.48M and capital expenditures -1.55M, giving a free cash flow of 64.92M billion.
Operating Cash Flow66.48M
Free Cash Flow64.92M
Free Cash Flow per Share0.38
Dividends & Yields
Xeris Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.20
52-Week Price Change17.97%
50-Day Moving Average7.63
200-Day Moving Average7.06
Relative Strength Index (RSI)33.77
Average Volume (3m)2.03K
Important Dates
Xeris Pharmaceuticals upcoming earnings date is Nov 5, 2026, Before Open (Confirmed).
Last Earnings DateAug 6, 2026
Next Earnings DateNov 5, 2026
Ex-Dividend Date―
Financial Position
Xeris Pharmaceuticals as a current ratio of 2.19, with Debt / Equity ratio of -2973.52%
Current Ratio2.19
Quick Ratio1.57
Debt to Market Cap0.03
Net Debt to EBITDA-5.77
Interest Coverage Ratio0.86
Taxes
In the past 12 months, Xeris Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Xeris Pharmaceuticals EV to EBITDA ratio is 93.32, with an EV/FCF ratio of 42.47.
EV to Sales4.06
EV to EBITDA93.32
EV to Free Cash Flow42.47
EV to Operating Cash Flow41.43
Balance Sheet
Xeris Pharmaceuticals has $121.75M in cash and marketable securities with $289.44M in debt, giving a net cash position of -$167.69M billion.
Cash & Marketable Securities$121.75M
Total Debt$289.44M
Net Cash-$167.69M
Net Cash Per Share-$0.97
Tangible Book Value Per Share-$0.61
Margins
Gross margin is 83.34%, with operating margin of 8.53%, and net profit margin of 0.19%.
Gross Margin83.34%
Operating Margin8.53%
Pretax Margin0.19%
Net Profit Margin0.19%
EBITDA Margin4.36%
EBIT Margin0.19%
Analyst Forecast
The average price target for Xeris Pharmaceuticals is $11.40, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$11.40
Price Target Upside35.71% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast41.47%
EPS Growth Forecast―